Effects of Insulin-like Growth Factor Binding Protein-3 and Farnesyltransferase Inhibitor SCH66336 on Akt Expression and Apoptosis in Non-Small-Cell Lung Cancer Cells
Authors:
- Ho-Young LeeHLHo-Young Lee
- Hojin MoonHMHojin Moon
- Kyung-Hee ChunKCKyung-Hee Chun
- Yoon-Soo ChangYCYoon-Soo Chang
- Khaled HassanKHKhaled Hassan
- Lin JiLJLin Ji
- Reuben LotanRLReuben Lotan
- Fadlo R. KhuriFKFadlo R. Khuri
- Waun Ki HongWHWaun Ki Hong
Open Access
- 19 October 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 96 (20) , 1536-1548
Abstract
Background: Overexpression of insulin-like growth factor binding protein-3 (IGFBP-3) induces apoptosis in non–small-cell lung cancer (NSCLC) cells in vitro and in vivo . However, Ras-mediated signaling pathways could develop resistance to apoptotic activities of IGFBP-3 in NSCLC cells. We thus evaluated the therapeutic potential of the combination of IGFBP-3 and SCH66336, a farnesyltransferase inhibitor that blocks Ras activation, in NSCLC cell lines. Methods: The effects of the combination of adenoviral IGFBP-3 (Ad-IGFBP3) and SCH66336 on proliferation and apoptosis of NSCLC cell lines (H1299, H596, A549, H460, H358, H322, and H226B) were assessed in vitro and in vivo by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, a flow cytometry–based terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick-end labeling assay, western blot analyses, and an NSCLC xenograft tumor model. The specific effects of Ad-IGFBP 3 and SCH66336 on mitogen-activated protein kinase and Akt were assessed by using adenoviral vectors that express constitutively active MEK1 or constitutively active Akt. Synergy was assessed by median effect analysis. Results: The combination of Ad-IGFBP3 and SCH66336 had synergistic antiproliferative effects in five cell lines (H1299, H596, A549, H460, and H322). Antiproliferative effects were accompanied by increased apoptosis in H460 cells in vitro . Overexpression of a constitutively active Akt but not a constitutively active MEK-1 rescued H460 cells from apoptosis induced by single or combined treatment of Ad-IGFBP3 and SCH66336. In H1299 tumor xenografts, Ad-IGFBP3 and SCH66336 was associated with decreased tumor volume, increased apoptosis, and decreased Akt levels. Conclusions: The combination of Ad-IGFBP3 and SCH66336 decreased Akt expression and increased apoptosis in NSCLC cells in vitro and in vivo . Simultaneous treatment with IGFBP-3 and SCH66336 may have the potential to be an effective therapeutic strategy in NSCLC.Keywords
This publication has 33 references indexed in Scilit:
- Role of IFN-γ and IL-2 in rat lung epithelial cell migration and apoptosis after oxidant injuryAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signalingOncogene, 2003
- Role of the IGF‐I receptor in the regulation of cell–cell adhesion: Implications in cancer development and progressionJournal of Cellular Physiology, 2002
- Insulin-Like Growth Factor I, IGF-Binding Protein 3, and Lung Cancer Risk in a Prospective Study of Men in ChinaJNCI: Journal of the National Cancer Institute, 2002
- Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinaseOncogene, 2001
- ADAM 12-S Cleaves IGFBP-3 and IGFBP-5 and Is Inhibited by TIMP-3Biochemical and Biophysical Research Communications, 2000
- Anticancer drug targets: growth factors and growth factor signalingJournal of Clinical Investigation, 2000
- Oncogenic ras Causes Resistance to the Growth Inhibitor Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) in Breast Cancer CellsJournal of Biological Chemistry, 1999
- Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migrationNature Medicine, 1998
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993